The surgeries were performed at France’s CHU Saint-Ètienne and at Rome’s Policlinico A. Gemelli Foundation, the Research Triangle, N.C.-based company said, by Dr. Celine Chauler, Dr. Salvatore Aletti and Dr. Gabriele Barabino.
“Patients are consistently interested in the least invasive approach possible. Utilizing 3mm microlap instruments with the Senhance Surgical Robot creates a virtually scarless approach with the precision of robotics to control such small instruments with delicate haptic force feedback,” Dr. Barabino said in a prepared statement.
The system was used in multiple general surgical and gynecologic procedures, including an ovarian cystectomy, endometrial excision, total laparoscopic hysterectomy, bilateral salpingo-oophorectomy and cholecystectomy, TransEnterix said.
“Microlaparoscopy with robotic assistance is now a reality utilizing Senhance. The use of microlaparoscopy is a growing trend, but it can be challenging to manually control and stabilize such small instruments. We believe Senhance robotic assistance can enable surgeons to expand their use of virtually scarless surgery in more patients, and creates an additional way robotics can bring value over traditional manual approaches,” CEO Todd Pope said in a press release.
In May, TransEnterix said it took out a $17 million term loan with an affiliate of Innovatus Capital Partners that it plans to use to get its Senhance robot-assisted surgery platform past the FDA.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.